Zequan Zheng

Zequan Zheng

Auto-generated profile, based on publicly available information

Zequan Zheng

Department of Neurology, The Second Affiliated Hospital of Guangzhou University of Chinese Medicine, Guangdong Provincial Hospital of Chinese Medicine, Guangzhou, Guangdong 510120, China

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 April 2022 in Bioengineered
Verified
Journal Article
Open access
KZKenan Zheng
Kenan Zheng
BLBaojiang Lv
Baojiang Lv
LWLulu Wu
Lulu Wu
CWChen Wang
Chen Wang
HXHaoyou Xu
Haoyou Xu
ZZZequan Zheng
Zequan Zheng
Experimental autoimmune encephalomyelitis (EAE) is characterized by demyelination of the central nervous system. Emodin is an anthraquinone derivative with comprehensive anti-inflammatory, anti-cancer, and immunomodulatory effects and is widely used in the treatment of inflammatory, tumor, and immune system diseases. However, none of the clinical or experimental studies have explored the therapeutic efficacy of emodin in EAE/multiple sclerosis (MS). Thus, we evaluated the protective effect of emodin on EAE mediated via inhibition of microglia activation and inflammation. Wild-type mice were randomly divided into the normal control, EAE, low-dose emodin, and high-dose emodin groups. Clinical scores and pathological changes were assessed 21 days after immunization. The network pharmacology approach was used to elucidate the underlying mechanisms by using an online database. Molecular docking, polymerase-chain reaction tests, western blotting, and immunofluorescence were performed to verify the network pharmacology results. An in vivo experiment showed that high-dose emodin ameliorated clinical symptoms, inflammatory cell infiltration, and myelination. Pharmacological network analysis showed AKT1 was the main target and that emodin played a key role in MS treatment mainly via the PI3K–Akt pathway. Molecular docking showed that emodin bound well with PI3K, AKT1, and NFKB1. Emodin decreased the expression of phosphorylated(p)-PI3K, p-Akt, NF-κB, and myeloid differentiation factor 88 and the levels of markers (CD86 and CD206) in M1- and M2-phenotype microglia in EAE. Thus, the emodin inhibited microglial activation and exhibited anti-inflammatory and neuroprotective effects against EAE via the Myd88/PI3K/Akt/NF-κB signalling pathway. In conclusion, emodin has a promising role in EAE/MS treatment, warranting further detailed studies.

29 January 2024 in Frontiers in Immunology
Verified
Journal Article
Open access
HOHuiying Ouyang
Huiying Ouyang
XLXiaojun Li
Xiaojun Li
HXHaoyou Xu
Haoyou Xu
YZYibo Zhan
Yibo Zhan
ZZZequan Zheng
Zequan Zheng
ZMzhao min
zhao min
Background: Pain is a common symptom in multiple sclerosis (MS), especially neuropathic pain, which has a significant impact on patients’ mental and physical health and quality of life. However, risk factors that related to neuropathic pain, still remain unclear.Objective: The study aimed to explore the risk factors of neuropathic pain among MS patients.Materials and methods: This retrospective study examined the consecutive patients diagnosed with MS in the Department of Neurology of Guangdong Provincial Hospital of Chinese Medicine between August 2011 and October 2022. Neuropathic pain was defined as “pain arising as a direct consequence of a lesion or disease affecting the somatosensory system”. Demographic and clinical features were obtained from the electronic system of the hospital.Results: Our cohort revealed that the prevalence of patients with neuropathic pain in MS was 34.1%. The results indicated that the longer the spinal lesions, the greater the neuropathic pain risks (2-4: OR, 13.3(2.1-82), >5: OR, 15.2(2.7-86.8), p for tread: 0.037). Meanwhile, multivariate regression analysis showed that cervical and thoracic lesions (OR 4.276, 95% CI 1.366-13.382, P = 0.013), upper thoracic lesions (T1-T6) (OR 3.047, 95% CI 1.018-9.124, P = 0.046) were positively correlated with neuropathic pain, while basal ganglia lesions (OR 0.188, 95% CI 0.044-0.809, P = 0.025) were negatively correlated with neuropathic pain among MS patients.Conclusion: Extended spinal lesions (≥3 spinal lesions), cervical and thoracic lesions, upper thoracic lesions were independent risk factors of neuropathic pain among MS patients. Furthermore, our study found that the longer the spinal lesions, the greater the neuropathic pain risks.

20 November 2024 in Frontiers in Medicine
Verified
Journal Article
Open access
PDF file
ZZZequan Zheng
Zequan Zheng
FCFajun Chen
Fajun Chen
LQLulu Qin
Lulu Qin
ALAili Lu
Aili Lu
HXHaoyou Xu
Haoyou Xu
ZYzhao yuanqi
zhao yuanqi
Balamuthia mandrillaris is a kind of brain-eating amoeba leading to granulomatous amoebic encephalitis (GAE) with a high mortality rate and limited effective treatment options. Its underlying pathological mechanisms are still poorly understood. Here, we presented a 58-year-old man with Balamuthia mandrillaris meningoencephalitis, who died 33 days after onset. In this unique case, we introduced the use of ventriculoscopy in the treatment of B. mandrillaris meningoencephalitis. Through ventriculoscopy, we observed that the inflammatory response triggered by the disease was diffuse and extensive throughout the ventricles and meninges, not limited to the region of parasite invasion. Furthermore, under the precise guidance of ventriculoscopy, we implemented drug lavage therapy and intraventricular drainage, which, to a certain extent, managed to mitigate the progression of hydrocephalus and intracranial hypertension. Despite the unfortunate outcome of the patient’s death due to brainstem hemorrhage, we reiterate the crucial role that surgical intervention plays in both diagnosing and managing amoebic encephalitis. This underscores the need for continued research and innovation in surgical techniques to enhance patient outcomes and combat this challenging neurological condition.

26 April 2025 in Journal of Stroke and Cerebrovascular Diseases
Verified
Journal Article
Open access
LQLulu Qin
Lulu Qin
LPLilin Peng
Lilin Peng
YSYifan Sun
Yifan Sun
GCGuixian Chen
Guixian Chen
CDChenghao Du
Chenghao Du
ZZZequan Zheng
Zequan Zheng
This study aims to explore the effects and mechanisms of Shengjiang Powder (SJP) in alleviating ischemic stroke. The middle cerebral artery occlusion and reperfusion (MCAO) model was established in rats for both the model and medication groups. Neurological function scores, TTC staining, Hematoxylin-Eosin staining and Nissl staining were employed to evaluate the preventive and therapeutic effects of SJP on MCAO in rats. Real-time quantitative polymerase chain reaction, western blotting, and immunofluorescence double staining were used to detect the expression levels of biological markers related to the NLRP3/Caspase-1 pathway. SJP demonstrated an improvement in brain tissue damage in rats subjected to MCAO. SJP inhibited the activation of the NLRP3/Caspase-1 pathway after MCAO in rats. Caspase-1 was primarily expressed in neurons and microglia 24 h post-MCAO in rats, with minimal expression in astrocytes. SJP ameliorates brain tissue damage by inhibiting the activation of the NLRP3/Caspase-1 pathway, thereby reducing the inflammatory response and cell pyroptosis induced by MCAO in rats.